TY - JOUR
T1 - New strategies for the prevention of radiation injury
T2 - possible implications for countering radiation hazards of long-term space travel.
AU - Seed, Thomas
AU - Kumar, Sree
AU - Whitnall, Mark
AU - Srinivasan, Venkataraman
AU - Singh, Vijay
AU - Elliott, Thomas
AU - Landauer, Michael
AU - Miller, Alexandra
AU - Chang, Cheng Min
AU - Inal, Cyndi
AU - Deen, Jason
AU - Gehlhaus, Martin
AU - Jackson, William
AU - Hilyard, Edward
AU - Pendergrass, James
AU - Toles, Raymond
AU - Villa, Vilmar
AU - Miner, Venita
AU - Stewart, Michael
AU - Benjack, James
AU - Danilenko, Dimitry
AU - Farrell, Ckatherine
PY - 2002/12
Y1 - 2002/12
N2 - New strategies for the prevention of radiation injuries are currently being explored with the ultimate aim of developing globally radioprotective, nontoxic pharmacologics. The prophylactic treatments under review encompass such diverse pharmacologic classes as novel immunomodulators, nutritional antioxidants, and cytokines. An immunomodulator that shows promise is 5-androstenediol (AED), a well-tolerated, long-acting androstene steroid with broad-spectrum radioprotective attributes that include not only protection against acute tissue injury, but also reduced susceptibility to infectious agents, as well as reduced rates of neoplastic transformation. Other potentially useful radioprotectants currently under study include the nutraceutical vitamin E and analogs, a chemically-engineered cytokine, interleukin-1beta, and a sustained-release formulation of an aminothiol, amifostine. Results suggest that a new paradigm is evolving for the prophylaxes of radiation injuries, based on use of newly identified, nontoxic, broad-spectrum prophylactic agents whose protective action may be leveraged by subsequent postexposure use of cytokines with organ-specific reparative functions.
AB - New strategies for the prevention of radiation injuries are currently being explored with the ultimate aim of developing globally radioprotective, nontoxic pharmacologics. The prophylactic treatments under review encompass such diverse pharmacologic classes as novel immunomodulators, nutritional antioxidants, and cytokines. An immunomodulator that shows promise is 5-androstenediol (AED), a well-tolerated, long-acting androstene steroid with broad-spectrum radioprotective attributes that include not only protection against acute tissue injury, but also reduced susceptibility to infectious agents, as well as reduced rates of neoplastic transformation. Other potentially useful radioprotectants currently under study include the nutraceutical vitamin E and analogs, a chemically-engineered cytokine, interleukin-1beta, and a sustained-release formulation of an aminothiol, amifostine. Results suggest that a new paradigm is evolving for the prophylaxes of radiation injuries, based on use of newly identified, nontoxic, broad-spectrum prophylactic agents whose protective action may be leveraged by subsequent postexposure use of cytokines with organ-specific reparative functions.
UR - http://www.scopus.com/inward/record.url?scp=0038678495&partnerID=8YFLogxK
U2 - 10.1269/jrr.43.s239
DO - 10.1269/jrr.43.s239
M3 - Article
C2 - 12793766
AN - SCOPUS:0038678495
SN - 0449-3060
VL - 43 Suppl
SP - S239-244
JO - Journal of radiation research
JF - Journal of radiation research
ER -